FT in diagnostic of HBV

Prognostic Value of FibroTest in HCVPrognostic Value of FibroTest in HCV

Ngo et al, ClinChem 2006“A Prospective Analysis of the prognostic value of biomarkers

(FirboTest) in patients with chronic hepatitis C”

FT in diagnostic of HBV

Study designStudy design

• Included patients

FT in diagnostic of HBV

5 year survival curves according to FibroTest 5 year survival curves according to FibroTest severity groups at baseline severity groups at baseline FT classifies corectly FT classifies corectly

Survival without HCV complications (group 1, no or minimal fibrosis; patients with baseline FibroTest of 0.00–0.31.)

Survival rate without HCV complications : 93% [95% confidence interval (CI), 91%–96%; 29 complications]

FT 0.96 vs Biopsy 0.91 P=0.01Pugh 0.80 P=0.006

APRI 0.82 P=0.03Forns 0.86 P=0.04

Survival without HCV related death (group 2, moderate fibrosis: patients with baseline FibroTest of 0.32–0.58.)

Survival without HCV related death: 98% (95% CI, 96%–99%; 9 deaths). FT 0.96 vs Biopsy 0.87 P=0.04

Pugh 0.89 P=NS APRI 0.82 P=0.02

Forns 0.87 P=0.04

Overall Survival(group 3, severe fibrosis: patients with baseline FibroTest of 0.58–1.00.)

Overall survival : 95% (95% CI, 93%–97%; 20 deaths), which was lower, although not substantially, than that for paired controls (97%; 95% CI, 97%–98%; P = 0.06)

Overall survival of the untreated severe group was substantially lower than that of paired Controls

FT in diagnostic of HBV

Prognostic value ROC of FibroTest and biopsyPrognostic value ROC of FibroTest and biopsy

FibroTest vs biopsy fibrosis staging for survival without HCV-related complications.

FibroTest AUROC (0.96; 95% CI, 0.93%–0.97%) was greater than fibrosis staging AUROC (0.91; 95% CI, 0.85%–0.94%; P=0.01)

FibroTest vs biopsy fibrosis staging for survival without HCV-related death.

FibroTest AUROC (0.96; 95% CI, 0.93%–0.98%) was greater than fibrosis staging AUROC (0.87; 95% CI, 0.70%–0.94%; P =0.046).

FibroTest vs biopsy fibrosis staging for overall survival. FibroTest AUROC (0.76; 95% CI, 0.63%– 0.84%) was not

substantially different from fibrosis staging AUROC (0.66; 95% CI, 0.52%–0.78%).

FibroTest

Biopsy

FibroTest

Biopsy

FibroTest

Biopsy

FT in diagnostic of HBV

ConclusionsConclusions

• FibroTest has prognostic values at least similar to that of liver biopsy, with the advantage of being non invasive

• FibroTest has significant better prognostic values than that of other non invasive biomarkers

FT in diagnostic of HBV